SCHEMBL23212067

SCHEMBL23212067

CC(c1ccc(C(F)(F)F)cc1)C1CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.48
RORC P51449 1/20 0.47
GPR119 Q8TDV5 2/20 0.44
MMP13 P45452 1/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NR1H2 P55055 1/20 0.43
NR1H3 Q13133 1/20 0.43
USP30 Q70CQ3 1/20 0.42
TEAD1 P28347 2/20 0.42
TACR1 P25103 5/20 0.41
P2RY14 Q15391 1/20 0.41
DPP4 P27487 2/20 0.40
DPP7 Q9UHL4 2/20 0.40
DPP8 Q6V1X1 1/20 0.40
STS P08842 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23211926 0.88 MMP13 (0.54) MAPTGPR119MMP13NPC1ALDH1A1
SCHEMBL23830783 0.84 USP30 (0.48) MAPTRORCGPR119NPC1ALDH1A1
SCHEMBL23211906 0.82 MAPT (0.46) MAPTRORCGPR119NPC1ALDH1A1
SCHEMBL23211870 0.82 DPP4 (0.46) L3MBTL1TEAD1DPP4DPP7DPP8
SCHEMBL19734532 0.79 DPP4 (0.42) MAPTRORCGPR119MMP13NPC1
SCHEMBL17729471 0.79 MAPT (0.52) MAPTRORCGPR119MMP13NR1H2
SCHEMBL22059421 0.79 RORC (0.57) MAPTRORCGPR119TACR1P2RY14
SCHEMBL4241240 0.78 MAPT (0.52) MAPTGPR119MMP13NPC1ALDH1A1
SCHEMBL4240027 0.78 MAPT (0.52) MAPTGPR119MMP13NPC1ALDH1A1
SCHEMBL14528997 0.76 CCR5 (0.51) MAPTGPR119NPC1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111936503-B Oxazine monoacylglycerol lipase (MAGL) inhibitors 豪夫迈·罗氏有限公司 2023-09-12 CN disclosed
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 EP disclosed
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC MAPT 4181/4885RORC 2754/4885GPR119 432/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC MAPT 4181/4885RORC 2754/4885GPR119 432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.